Presentation at ERS

Vectura Group plc

Presentation at ERS

Chippenham, UK - 5 September 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), advises that the following presentation will be made at 8:30am CEST, 9 September at the European Respiratory Society (ERS) International Congress 2014, being held in Munich, Germany, 6-10 September 2014.

Vectura will present data at the European Respiratory Society International Congress 2014

Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition

Data to be presented at ERS by Vectura will include:

Lung function data (FEV1 and FEF25-75) from a clinical study in oral corticosteroid dependent asthma patients (GINA V) using the AKITA Jet inhalation system with FAVORITE technology to deliver Budesonide to the small airways as add on therapy.

It shows that lung function did significantly improve under therapy.

The abstract will be presented by Dr. Sebastian Canisius in a Poster Discussion Session: Novel approaches and evidence for drug development in respiratory diseases on Tuesday, 9 September, 8:30am - 10:30am CEST, Room M-1 (B0), Session 365.

Enquiries

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.1

Vectura has eight products marketed by partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has disclosed development collaborations and licence agreements with several pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company Limited.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.

References

1 Pharmaview Commercial Landscape Series Respiratory Decision Resources 2013

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.